WO2000002913A1 - Chemotaxis-inhibiting protein of staphylococcus (chips) and its use - Google Patents
Chemotaxis-inhibiting protein of staphylococcus (chips) and its use Download PDFInfo
- Publication number
- WO2000002913A1 WO2000002913A1 PCT/NL1999/000442 NL9900442W WO0002913A1 WO 2000002913 A1 WO2000002913 A1 WO 2000002913A1 NL 9900442 W NL9900442 W NL 9900442W WO 0002913 A1 WO0002913 A1 WO 0002913A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- column
- protein
- chips
- biologically active
- chromatography column
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a new protein which can be used in the treatment of inflammation reactions.
- the invention further relates to a method of purifying the protein.
- the invention relates to a screening test with which analogous proteins can be detected.
- An inflammation reaction is very generally a process wherein defence cells make their way to a source of infection and there ensure the elimination of the cause.
- Different mediators are herein released which contribute to elimination but also produce the inflammation symptoms.
- a distinction can be made between acute inflammations (such as sepsis) and latent chronic inflammations (such as rheumatism) . In people with a lowered resistance acute inflammations can occur more often and more severely (as in the case of AIDS) .
- a chemotactic substance is present in a gradient along which the leucocytes move in a directed manner.
- the source of a chemotactic agent can be the bacteria itself. These agents are for instance small proteins with a terminal formyl group, such as fM P (N-formyl-Methionyl- Leucyl-Phenylalanine) .
- chemotactic agents are activated complement factors (the anaphyloxins C3a and C5a) , leukotrienes (such as TB4 (Leukotriene B4) and PAF (Platelet-Activating Factor) and chemokines produced by different cell types such as interleukin-8 (monocytes and endothelial cells) , RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted) , eotaxin, MCP (Monocyte Chemotactic Protein) , MIP (Macrophage Inflammatory Protein) and others .
- complement factors the anaphyloxins C3a and C5a
- leukotrienes such as TB4 (Leukotriene B4) and PAF (Platelet-Activating Factor)
- chemokines produced by different cell types such as interleukin-8 (monocytes and endothelial cells) , RANTES (Regulated upon Activation, Normal T-cell Ex
- chemokines are only specific to a determined type of leucocyte, others affect a plurality of cells.
- the receptors for chemokines are subdivided into two main groups, the CC and CXC receptors which all belong to the serpentines, receptors which traverse the membrane 7 times.
- the serpentines are rhodopsin-like GTP- binding protein linked receptors.
- the super family of chemotactic cytokines, chemokines is characterized by 4 conserved cysteines. Depending on the relative position of the first two cysteines, two families can be distinguished: the CXC or alpha-chemokines and the CC or beta-chemokines .
- the CXC chemokines are particularly active on granulocytes while the CC chemokines activate a wide range of leucocytes including monocytes, eosinophils, T-lymphocytes, NK cells and dendritic cells.
- This family of chemokines and also the classical chemotactic agents such as f LP and C5a bind and activate the serpentines.
- CCR5 and CXCR4 chemokine receptors
- CXCR4 chemokine receptors
- people with a genetic variant of the CCR5 receptor consisting of a 32 base pair * deletion are found to be resistant to infection with HIV.
- chemokines are also potent activators or primers of other leucocyte functions. It is therefore desirable to achieve a blocking of chemokines whereby inflammation reactions can be kept in check. It is therefore the object of the present invention to provide a new agent with inflammation- inhibiting properties for the treatment of acute and chronic inflammation reactions and HIV.
- a protein was found in the extracellular medium of growing Staphylococcus aureus (S. aureus) which was found capable of blocking different chemokine receptors .
- chemokine receptors both of the expression of receptors of classical chemotactic agents such as fMLP and C5a on granulocytes and of the expression of CXCR4 and CCR5 receptors on lymphocytes, monocytes and macrophages .
- the reduced receptor expression was related to greatly reduced chemotaxis relative to the chemokines, as well as a reduced infection with HIV.
- the activity of the protein is already manifest in the culture supernatant of the growing S . aureus .
- the active protein was also purified by means of a number of Ligand Dye columns. A pre-purification was first performed on a so- called “yellow column” ("Reactive Yellow 86" ligand dye cross- linked 4% beaded agarose column (Sigma) ) , followed by an absorption chromatography column (the so-called
- the DNA column removes a contaminant with the same molecular weight as the protein according to the invention.
- the absorption chromatography column concentrates the protein and is selective for the protein.
- a post-purification also takes place by means of gel filtration and optionally a concentration. In the gel filtration the protein with the molecular weight of about 17 kD is selected. This is the protein according to the invention.
- Each step in the purification method can be monitored by means of testing the activity of the flow- through or the eluate of the different columns. This takes place by monitoring whether the flow-through or the eluate is able to prevent the binding of fMLP to granulocytes . An extensive test protocol is given in the examples .
- the first (N-terminal) 15 amino acids of the purified protein were determined by means of micro- sequencing. This sequence is given in figure 4. With sequence analysis no homology with any known bacterial or eucaryotic amino acid sequence was found in databases. This is therefore a new and unique protein.
- this protein is isolated from the supernatant of the Staphylococcus aureus and gives inhibition of chemotaxis, this protein is herein also designated as "CHIPS” : CHemotaxis Inhibitory Protein from Staphylococcus aureus .
- the present invention therefore relates according to a first aspect thereof to the CHIPS protein, which is characterized by: a) a molecular weight of about 17 kD; b) the N-terminal amino acid sequence as given in figure 4; and c) a biological activity which consists of the capacity to prevent the binding of fMLP to granulocytes in a test as described in example 1, and biologically active fragments thereof.
- the CHIPS protein influences the ⁇ chemotaxis of leucocytes to the source of the chemoattractant , such as the bacteria. It has been found according to the invention that the number of at least two receptors (fMLP and C5a) on the leucocytes, in particular granulocytes, is down-regulated. The down-regulation is reversible.
- the invention further relates to a therapeutic composition, comprising a suitable excipient and the CHIPS protein and/or biologically active fragments thereof.
- the composition can be used for the treatment of acute and chronic inflammation reactions and HIV infection.
- the protein ensures that the receptors which provide movement of the leucocyte to the chemotactic substance are blocked.
- the invention likewise relates to the CHIPS protein and/or biologically active fragments thereof for use in the treatment of acute and chronic inflammation reactions and HIV infection, as well as the use of the CHIPS protein and/or biologically active fragments thereof for the manufacture of a therapeutic preparation for the treatment of said symptoms .
- antibodies against the CHIPS protein and/or fragments thereof are provided for use in the treatment of staphylococcus infection.
- the proteins will block the activity of CHIPS or its fragments and thus restart the chemotaxis terminated by the bacteria, whereby the natural defence against the bacteria is restored.
- the therapeutic compositions which according to the invention contain CHIPS or antibodies thereagainst as active ingredient, will be particularly intended for parenteral, and then specifically, intravenous use.
- the therapeutic compositions can be prepared by combining (i.e. mixing, dissolving etc.) CHIPS with pharmaceutically acceptable excipients suitable for intravenous administration.
- the concentration of the active ingredient in a therapeutic composition can vary between 0.001% and 100%, depending on the nature of the treatment and the method of administration.
- the dose of the active ingredient for administering likewise depends on the administering route and application, but may for instance vary between 0.001 and 1 mg per kg of body weight, preferably between 1 ⁇ g and 100 ⁇ g per kg of body weight.
- the invention further relates to a method of purifying the CHIPS protein, comprising of: a) guiding over an absorption chromatography column the culture supernatant of Staphylococcus aureus or a liquid obtained therefrom after pre-purification; bl) subsequently guiding the flow- through of the absorption chromatography column first over an affinity chromatography column and thereafter guiding the eluate of the affinity chromatography column over a DNA column; or b2) subsequently guiding the flow- through of the absorption chromatography column first over a DNA column and thereafter guiding the flow-through of the DNA column over an absorption chromatography column; c) guiding the flow-through respectively the eluate of the last column of step b) over a gel filtration column and selecting the fraction with a molecular weight of about 17 kD.
- Flow- through is herein understood to mean that part of the loaded liquid having situated therein the constituents which come from the column without extra treatment. The constituents in this flow-through do not bind to the column.
- “Eluate” is understood to mean the liquid which comes from the column after elution and which contains the constituents from the liquid loaded on the column which were bound to the column and were released again therefrom by the elution.
- the absorption column binds most constituents of the loaded culture medium or a liquid obtained therefrom after pre-purification.
- the affinity column binds CHIPS and the Snase (Staphylococcal Nuclease) which has the same molecular weight as CHIPS and the same affinity (or lack thereof) for the affinity column respectively the absorption column.
- the DNA column binds only the Snase, whereby this is separated from CHIPS. This method works particularly well if the first affinity chromatography column is a so-called Ligand Dye "yellow” column, the second affinity chromatography column is a so-called Ligand Dye "green” column and the DNA column a DNA cellulose column.
- the invention also relates to a determination or assay for determining the activity of the CHIPS protein or proteins with an analogous function, comprising of: a) introducing into a first compartment labelled cells capable of chemotaxis, in particular leucocytes, b) introducing one or more chemoattractants into a second compartment separated from the first compartment by a membrane permeable to at least the cells, c) placing the protein for testing into the first compartment; d) measuring the quantity of label in the second compartment after a determined time.
- the cells are capable of moving through the membrane in the direction of the chemoattractant .
- the presence of CHIPS or an analogous protein prevents the migration by deactivating the receptor (s) for the chemoattractant (s) .
- This test can be applied more generally to also determine the chemotaxis-modulating activity of other substances. The method steps are then the same.
- CHIPS protein Proteins analogous to CHIPS which are found in this manner can be subjected to the same purification as CHIPS to thus be able to determine homology between the two .
- the CHIPS protein according to the invention has also been found in S .epidermis as well as in S . aureus .
- CHIPS was isolated from the culture supernatant of Staphylococcus aureus via the steps of ligand dye affinity and absorption chromatography, gel filtration and concentration, in addition to the testing of the activity of CHIPS on different chemokine receptors on different leucocytes and the testing of the inhibition of HIV infection in T-cells and macrophages is described in the examples following hereinbelow, which are only intended by way of illustration and are not intended to limit the invention in any way whatsoever.
- Figure 1 shows the incubation of granulocytes with a concentration series of a Staphylococcus supernatant (SaS) and the effect on the fMLP receptors and the C5a receptors .
- SaS Staphylococcus supernatant
- Figure 2 shows the effect of a concentration series of SaS on the chemotaxis of granulocytes to fMLP.
- Figure 3 shows the fractions of the gel filtration column with the optical density (OD) (line with diamonds) and the activity in the fMLP receptor assay as a percentage of inhibition (bars) .
- Figure 4 shows the sequence of the first 15 (N- terminal) amino acids of CHIPS (of the estimated 125 in total) .
- Figure 5a shows the incubation of granulocytes with a concentration series of purified CHIPS and the effect on the fMLP receptors and the C5a receptors.
- Figure 5b shows the incubation of granulocytes with a concentration series of purified CHIPS and the effect on the directed migration to fMLP.
- Staphylococcus aureus 1690 (a clinical isolate, Utrecht Teaching Hospital) or Staphylococcus aureus Newman (van Dr TJ Foster, Dublin) is cultured overnight in IMDM medium (Gibco) and subsequently diluted 1:40 in fresh IMDM for a 7 hour culture at 37 °C. After pelleting of the bacteria the S . aureus supernatant (referred to as SaS) is collected, filtered over a 0.2 ⁇ m filter and immediately used further. See also Veldkamp et al , Inflammation 21, 541-551 (1997) .
- a quantity of 2 litres of SaS is guided over three columns (25 ml) coupled in tandem. These three columns are successively a "Reactive Yellow 86" ligand dye cross-linked 4% beaded agarose column (Sigma) , a DNA Cellulose (Pharmacia) and a "Reactive Green 19" ligand dye cross-linked 4% beaded agarose column (Sigma) . After washing the green (Reactive Green 19) column is eluted with 2 M NaCl and the active fractions are pooled and concentrated lOx with polyethylene glycol . The concentrated material is separated on a Pharmacia Superdex-200 gel filtration column, whereafter the active fractions are pooled, concentrated, dialysed and freeze- dried. The final purified material is resuspended in a small volume of sterile water and used inter alia for micro-sequence analysis.
- Granulocytes are isolated from heparinized blood of healthy volunteers via a Histopaque-Ficoll gradient in accordance with the standard method (Troelstra et al , J. Leukocyte Biol . 61:173-178 (1997). The remaining erythrocytes in the granulocyte fraction are lysed with sterile water (for 30 sec) and washed after recovery of the isotonicity. The cells are finally resuspended in RPMI (Gibco) with 0.05% Human Serum Albumin (RPMI/HSA) .
- RPMI Human Serum Albumin
- a Transwel system consisting of an upper compartment and a lower compartment separated by a 3 ⁇ m polycarbonate membrane .
- the granulocytes are labelled with BCECF (2-carboxyethyl-5- (and-6- ) carboxyfluorescein; Molecular Probes) , a fluorescent label which enters the cytoplasm of the cells.
- the cells (5xl0 6 ) are incubated for 20 minutes at 22 °C with 3 ⁇ M BCECF-AM (the acetomethyl ester of 2-carboxyethyl-5- (and- 6-) -carboxyfluorescein) , subsequently washed three times and resuspended to 5xl0 6 cells/ml in RPMI/HSA.
- 100 ⁇ l of cells and the desired quantity of the CHIPS protein is introduced into the upper compartment of the Transwel system and the whole is suspended in the wells of a standard 24 -well microtitre plate (Costar) . Each well contains 600 ⁇ l RPMI/HSA with or without addition of the chemoattractant for testing.
- the chemoattractants are: recombinant C5a (Sigma) , recombinant interleukin-8 (Pepro Tech), Platelet Activating Factor-16 (PAF-16; Calbiochem) or fMLP (Sigma) . After 60 minutes incubation at 37 °C the Transwel container is lifted from the wells and the microtitre plate is analysed for fluorescence in a CyoFluorll (PerSeptiveBiosystems) . The degree of fluorescence is a direct measure for the number of granulocytes which has migrated through the membrane and is expressed as a percentage of the fluorescence of the added number of cells.
- Figure 1 shows the effect of the incubation of granulocytes with a concentration series of a Staphylococcus-supernatant (SaS) on the fMLP receptors and the C5a receptors. A strong down regulation of both the C5A and the fMLP receptor is visible.
- SaS Staphylococcus-supernatant
- Figure 2 shows that the chemotaxis (cell movement) to the attractant (fMLP) is strongly inhibited.
- Figure 3 shows that the strongest inhibiting activity is situated in the elution range between 240 and 280 ml.
- the volume fractions correspond here with a protein of about 17 kD.
- Figure 4 shows the sequence of the first 35 (N- terminal) amino acids of CHIPS (of the estimated 125 in total) .
- a synthetic peptide was made of the first 15 amino acids in accordance with standard Fmoc chemistry as described inter alia in De Haas et al , J. Immunol. 161:3607-3615 (1998) and Alonso de Velasco et al , Infect. Immun. 62:799-808 (1994).
- Antibodies generated against this peptide in rabbits (coupled to KLH in accordance with the instructions of the manufacturer, Pierce, and subcutaneously immunized with Freund's Complete Adjuvant, followed by a booster injection with Freund's Incomplete Adjuvant), as for instance described in Alonso de Velasco et al, supra , neutralize the activity of CHIPS.
- the expression of the different chemokine receptors is determined with specific fluorescent- labelled antibodies and flowcytometry .
- the procedure followed is analogous to that described under 1.2 in example 1.
- Use is made of the following monoclonals: S5/1, anti-CD88 (C5a receptor) from Serotec Ltd; SE2 , anti-CDwl28A (IL-8 receptor) from Alexis Corporation; anti-PAF Receptor from Alexis Corporation.
- After incubation with CHIPS the cells are incubated for 30 min on ice with 5 ⁇ g/ml antibody and after washing are labelled with a F (ab) 2-FITC-labelled goat anti-murine Ig (Dako) .
- the average fluorescence of the granulocytes is a measure for the quantity of receptor on the cell surface.
- the relative expression, after subtraction of the background value, is expressed as a percentage of the cells which are incubated with control buffer.
- Figure 5a shows that both the C5a receptor and the fMLP receptor also disappear from the surface of the cells due to purified CHIPS.
- Figure 5b shows the incubation of granulocytes with a concentration series of purified CHIPS and the effect on the directed migration to fMLP. It can be seen that the chemotaxis (cell movement) to fMLP is inhibited completely and dose-dependently by purified CHIPS.
- the mononuclear leucocytes (20% monocytes and 80% lymphocytes) are isolated from heparinized blood of healthy volunteers via a Ficoll gradient (Pharmacia) in accordance with the standard method (Antal-Szalmas et al , J. Leukocyte Biol . 61, 721-728 (1997) . After washing the cells are resuspended in RPMI/HSA. The procedure followed for measuring expression of the different chemokine receptors is the same as described under 2.1 in example 2. To measure the expression of the lymphotrophic co- receptor for HIV (CXCR4) use is made of monoclonal 12G5 anti-CXCR4 from Becton Dickinson.
- CXCR4 lymphotrophic co- receptor for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002333898A CA2333898A1 (en) | 1998-07-10 | 1999-07-12 | Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
BR9911944-7A BR9911944A (en) | 1998-07-10 | 1999-07-12 | Staphylococcus chemotaxis inhibitor protein (protein chips) and its use |
KR1020007015012A KR20010053290A (en) | 1998-07-10 | 1999-07-12 | Chemotaxis-inhibiting protein of Staphylococcus (CHIPS) and its use |
PL99345452A PL345452A1 (en) | 1998-07-10 | 1999-07-12 | Chemotaxis-inhibiting protein of staphylococcus |
EP99933284A EP1095059B1 (en) | 1998-07-10 | 1999-07-12 | Chemotaxis inhibiting protein of staphylococcus (chips) and its use |
IL14076899A IL140768A0 (en) | 1998-07-10 | 1999-07-12 | Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
NZ509051A NZ509051A (en) | 1998-07-10 | 1999-07-12 | Chemotaxis-inhibiting protein of staphylococcus (CHIPS) and its use |
JP2000559142A JP2002520336A (en) | 1998-07-10 | 1999-07-12 | Staphylococcus chemotaxis inhibitory protein (CHIPS) and uses thereof |
DE69931784T DE69931784T2 (en) | 1998-07-10 | 1999-07-12 | CHEMOTAXIC PROTEIN OF STAPHYLOCOCCUS AUREUS (CHIPS) AND ITS USE |
HU0102975A HUP0102975A2 (en) | 1998-07-10 | 1999-07-12 | Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
AU49359/99A AU4935999A (en) | 1998-07-10 | 1999-07-12 | Chemotaxis-inhibiting protein of (staphylococcus) (chips) and its use |
BG105120A BG105120A (en) | 1998-07-10 | 2001-01-08 | Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
NO20010140A NO20010140L (en) | 1998-07-10 | 2001-01-09 | Chemotaxin-inhibiting protein of Staphylococcus (CHIPS) and its use |
US11/063,324 US20050143307A1 (en) | 1998-07-10 | 2005-02-22 | Chemotaxis-inhibiting protein of staphyloccocus (CHIPS) and its use |
CY20061101273T CY1105343T1 (en) | 1998-07-10 | 2006-09-06 | STAPHYLOCCCAL CHEMOTACTIC INHIBITING PROTEIN (CHIPS) AND ITS USE |
US11/691,745 US20080242605A1 (en) | 1998-07-10 | 2007-03-27 | Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1009614 | 1998-07-10 | ||
NL1009614 | 1998-07-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/063,324 Continuation US20050143307A1 (en) | 1998-07-10 | 2005-02-22 | Chemotaxis-inhibiting protein of staphyloccocus (CHIPS) and its use |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000002913A1 true WO2000002913A1 (en) | 2000-01-20 |
WO2000002913B1 WO2000002913B1 (en) | 2000-03-30 |
Family
ID=19767471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL1999/000442 WO2000002913A1 (en) | 1998-07-10 | 1999-07-12 | Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
Country Status (22)
Country | Link |
---|---|
US (2) | US20050143307A1 (en) |
EP (1) | EP1095059B1 (en) |
JP (1) | JP2002520336A (en) |
KR (1) | KR20010053290A (en) |
CN (1) | CN1309662A (en) |
AT (1) | ATE328898T1 (en) |
AU (1) | AU4935999A (en) |
BG (1) | BG105120A (en) |
BR (1) | BR9911944A (en) |
CA (1) | CA2333898A1 (en) |
CY (1) | CY1105343T1 (en) |
DE (1) | DE69931784T2 (en) |
DK (1) | DK1095059T3 (en) |
ES (1) | ES2270609T3 (en) |
HU (1) | HUP0102975A2 (en) |
IL (1) | IL140768A0 (en) |
NO (1) | NO20010140L (en) |
NZ (1) | NZ509051A (en) |
PL (1) | PL345452A1 (en) |
PT (1) | PT1095059E (en) |
WO (1) | WO2000002913A1 (en) |
ZA (1) | ZA200100092B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1118663A1 (en) * | 2000-01-07 | 2001-07-25 | Universiteit Utrecht | Nucleic acids encoding chemotaxis inhibitory polypeptides |
WO2003006048A1 (en) * | 2001-07-11 | 2003-01-23 | Jari Pharmaceuticals B.V. | Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds |
WO2005005630A3 (en) * | 2003-07-08 | 2005-06-23 | Umc Utrecht Holding Bv | Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
WO2006011137A2 (en) | 2004-07-26 | 2006-02-02 | State Of Israel, Department Of Agriculture, Kimron Veterinary Institute | Novel bacteria and pharmaceutically active products obtained therefrom |
WO2010079314A3 (en) * | 2009-01-08 | 2010-09-10 | Alligator Bioscience Ab | Polypeptides and use thereof |
US8173774B2 (en) | 2006-04-20 | 2012-05-08 | Alligator Bioscience Ab | Polypeptides and use thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL345452A1 (en) * | 1998-07-10 | 2001-12-17 | Jari Pharmaceuticals Bv | Chemotaxis-inhibiting protein of staphylococcus |
US20020086292A1 (en) | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
EP1586583A3 (en) * | 2004-04-16 | 2005-11-16 | Alligator Bioscience AB (publ) | Compounds that block C5a complement receptor and their use in therapy |
GB2432366B (en) * | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987007146A1 (en) * | 1986-05-23 | 1987-12-03 | Regents Of The University Of Minnesota | INHIBITOR OF C5a-MEDIATED CHEMOTAXIS |
WO1993004202A1 (en) * | 1991-08-22 | 1993-03-04 | Washington University | Polynucleotide probes for salmonella |
US5514555A (en) * | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
WO1996040907A1 (en) * | 1995-06-07 | 1996-12-19 | Genetics Institute, Inc. | Interleukin-1 receptor intracellular ligand proteins and inhibitors of ligand binding |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514455A (en) * | 1994-07-08 | 1996-05-07 | Union Carbide Chemicals & Plastics Technology Corporation | Film extruded from an in situ blend of ethylene copolymers |
US7153655B2 (en) * | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
PL345452A1 (en) * | 1998-07-10 | 2001-12-17 | Jari Pharmaceuticals Bv | Chemotaxis-inhibiting protein of staphylococcus |
JP3722194B2 (en) * | 1999-05-20 | 2005-11-30 | セイコーエプソン株式会社 | Image display system |
EP1118663A1 (en) * | 2000-01-07 | 2001-07-25 | Universiteit Utrecht | Nucleic acids encoding chemotaxis inhibitory polypeptides |
US6958213B2 (en) * | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
US20020086292A1 (en) * | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
DE60312507T3 (en) * | 2002-05-17 | 2011-08-18 | Alligator Bioscience Ab | A METHOD FOR THE IN VITRO MOLECULAR EVOLUTION OF THE PROTEIN FUNCTION |
-
1999
- 1999-07-12 PL PL99345452A patent/PL345452A1/en unknown
- 1999-07-12 DE DE69931784T patent/DE69931784T2/en not_active Expired - Lifetime
- 1999-07-12 CA CA002333898A patent/CA2333898A1/en not_active Abandoned
- 1999-07-12 EP EP99933284A patent/EP1095059B1/en not_active Expired - Lifetime
- 1999-07-12 CN CN99808416A patent/CN1309662A/en active Pending
- 1999-07-12 KR KR1020007015012A patent/KR20010053290A/en not_active Application Discontinuation
- 1999-07-12 ES ES99933284T patent/ES2270609T3/en not_active Expired - Lifetime
- 1999-07-12 JP JP2000559142A patent/JP2002520336A/en active Pending
- 1999-07-12 BR BR9911944-7A patent/BR9911944A/en not_active IP Right Cessation
- 1999-07-12 WO PCT/NL1999/000442 patent/WO2000002913A1/en active IP Right Grant
- 1999-07-12 AU AU49359/99A patent/AU4935999A/en not_active Abandoned
- 1999-07-12 IL IL14076899A patent/IL140768A0/en unknown
- 1999-07-12 NZ NZ509051A patent/NZ509051A/en unknown
- 1999-07-12 PT PT99933284T patent/PT1095059E/en unknown
- 1999-07-12 HU HU0102975A patent/HUP0102975A2/en unknown
- 1999-07-12 AT AT99933284T patent/ATE328898T1/en not_active IP Right Cessation
- 1999-07-12 DK DK99933284T patent/DK1095059T3/en active
-
2001
- 2001-01-04 ZA ZA200100092A patent/ZA200100092B/en unknown
- 2001-01-08 BG BG105120A patent/BG105120A/en unknown
- 2001-01-09 NO NO20010140A patent/NO20010140L/en unknown
-
2005
- 2005-02-22 US US11/063,324 patent/US20050143307A1/en not_active Abandoned
-
2006
- 2006-09-06 CY CY20061101273T patent/CY1105343T1/en unknown
-
2007
- 2007-03-27 US US11/691,745 patent/US20080242605A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987007146A1 (en) * | 1986-05-23 | 1987-12-03 | Regents Of The University Of Minnesota | INHIBITOR OF C5a-MEDIATED CHEMOTAXIS |
WO1993004202A1 (en) * | 1991-08-22 | 1993-03-04 | Washington University | Polynucleotide probes for salmonella |
US5514555A (en) * | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
WO1996040907A1 (en) * | 1995-06-07 | 1996-12-19 | Genetics Institute, Inc. | Interleukin-1 receptor intracellular ligand proteins and inhibitors of ligand binding |
Non-Patent Citations (2)
Title |
---|
VELDKAMP ET AL.: "A novel neutrophil-chemotaxis inhibitory protein of Staphylococcus aureus", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 38, 1998 - 27 September 1998 (1998-09-27), pages 24 - 27, XP000862866 * |
VELDKAMP ET AL.: "Specific downregulation of neutrophil chemotaxis by staphylococcal culture supernates", ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 97, 1997 - 8 May 1998 (1998-05-08), pages 217, XP000857074 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1118663A1 (en) * | 2000-01-07 | 2001-07-25 | Universiteit Utrecht | Nucleic acids encoding chemotaxis inhibitory polypeptides |
WO2001049711A3 (en) * | 2000-01-07 | 2001-12-27 | Jari Pharmaceuticals B V | Nucleic acids encoding (poly)peptides having chips activity |
US7081513B2 (en) | 2000-01-07 | 2006-07-25 | Alligator Bioscience Ab | Nucleic acids encoding (poly) peptides having chips activity |
US7388078B2 (en) | 2000-01-07 | 2008-06-17 | Alligator Bioscience Ab | Nucleic acids encoding polypeptides having chips activity |
WO2003006048A1 (en) * | 2001-07-11 | 2003-01-23 | Jari Pharmaceuticals B.V. | Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds |
WO2005005630A3 (en) * | 2003-07-08 | 2005-06-23 | Umc Utrecht Holding Bv | Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
WO2006011137A2 (en) | 2004-07-26 | 2006-02-02 | State Of Israel, Department Of Agriculture, Kimron Veterinary Institute | Novel bacteria and pharmaceutically active products obtained therefrom |
WO2006011137A3 (en) * | 2004-07-26 | 2006-03-30 | State Of Israel Dept Of Agricu | Novel bacteria and pharmaceutically active products obtained therefrom |
US8173774B2 (en) | 2006-04-20 | 2012-05-08 | Alligator Bioscience Ab | Polypeptides and use thereof |
WO2010079314A3 (en) * | 2009-01-08 | 2010-09-10 | Alligator Bioscience Ab | Polypeptides and use thereof |
US8552149B2 (en) | 2009-01-08 | 2013-10-08 | Alligator Bioscience Ab | Polypeptides and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US20050143307A1 (en) | 2005-06-30 |
AU4935999A (en) | 2000-02-01 |
DE69931784D1 (en) | 2006-07-20 |
DE69931784T2 (en) | 2007-06-14 |
BG105120A (en) | 2001-11-30 |
US20080242605A1 (en) | 2008-10-02 |
DK1095059T3 (en) | 2006-10-02 |
BR9911944A (en) | 2001-09-25 |
EP1095059A1 (en) | 2001-05-02 |
NO20010140D0 (en) | 2001-01-09 |
HUP0102975A2 (en) | 2001-11-28 |
ES2270609T3 (en) | 2007-04-01 |
JP2002520336A (en) | 2002-07-09 |
IL140768A0 (en) | 2002-02-10 |
WO2000002913B1 (en) | 2000-03-30 |
CY1105343T1 (en) | 2010-03-03 |
NZ509051A (en) | 2003-01-31 |
NO20010140L (en) | 2001-03-01 |
PL345452A1 (en) | 2001-12-17 |
CA2333898A1 (en) | 2000-01-20 |
ATE328898T1 (en) | 2006-06-15 |
KR20010053290A (en) | 2001-06-25 |
ZA200100092B (en) | 2001-07-23 |
CN1309662A (en) | 2001-08-22 |
PT1095059E (en) | 2006-10-31 |
EP1095059B1 (en) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080242605A1 (en) | Chemotaxis-inhibiting protein of staphylococcus (chips) and its use | |
US5621077A (en) | Soluble IFN-β2/IL-6 binding protein its preparation, and pharmaceutical compositions containing it | |
Struyf et al. | Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor | |
Lanar et al. | Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice | |
CA1337518C (en) | Monoclonal antibodies against tnf-, hybridomas producing them and method for the purification of tnf- | |
Lett-Brown et al. | Chemotactic responses of normal human basophils to C5a and to lymphocyte-derived chemotactic factor | |
EP0412486B1 (en) | Antibodies to TNF binding protein I and F (ab) fragments thereof | |
Taverne et al. | Malarial parasites and tumour cells are killed by the same component of tumour necrosis serum. | |
Sylvester et al. | Secretion of neutrophil attractant/activation protein by lipopolysaccharide-stimulated lung macrophages determined by both enzyme-linked immunosorbent assay and N-terminal sequence analysis | |
JP2012501708A (en) | Treatment of inflammatory conditions | |
JPH0742317B2 (en) | Interferon protein and its production method | |
KR100542934B1 (en) | Amino-terminally truncated rantes as chemokine antagonists | |
Chandrashekar et al. | Serum dependent cell‐mediated immune reactions to Brugia pahangi infective larvae | |
Yoshida et al. | The production of anti-guinea pig lymphokine antibody | |
Groenewegen et al. | Supernatants of human leukocytes contain mediator, different from interferon gamma, which induces expression of MHC class II antigens. | |
Griffiths-Johnson et al. | [16] Animal models of asthma: Role of chemokines | |
EP0485471B1 (en) | Natural human anti-gamma interferon antibodies detected and purified by synthetic peptides | |
Ryan et al. | Characterization and purification of mouse macrophage procoagulant-inducing factor. | |
EP1244790B1 (en) | Nucleic acids encoding polypeptides having chips activity | |
Ware et al. | Mechanisms of lymphocyte-mediated cytotoxicity. II. biochemical and serologic identification of a precursor lymphotoxin form (pre-LT) produced by MLC-sensitized human T lymphocytes in vitro. | |
Shigeoka et al. | Neutrophil mobilization induced by complement fragments during experimental group B streptococcal (GBS) infection. | |
Barker et al. | The chemoattractant des-Arg74-C5a regulates the expression of its own receptor on a monocyte-like cell line. | |
Rot | In flammatory and physiological roles of chemokines | |
Goren et al. | Normal immunosuppressive protein. Isolation of a glycoprotein active fraction. | |
Potter et al. | Separation and purification of lymphocyte chemotactic factor (LCF) and interleukin 2 produced by human peripheral blood mononuclear cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99808416.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 509051 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007015012 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/00092 Country of ref document: ZA Ref document number: 200100092 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2000 559142 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 140768 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 1999 105120 Country of ref document: BG Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2333898 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/36/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 49359/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999933284 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09743364 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999933284 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007015012 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007015012 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999933284 Country of ref document: EP |